Quantcast

Cynosure Enhances Industry-Leading Smartlipo Family with 1440 nm Wavelength

October 22, 2009

WESTFORD, Mass., Oct. 22 /PRNewswire-FirstCall/ — Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the introduction of Smartlipo Triplex(TM), the world’s first laser lipolysis solution featuring three wavelengths that combine to deliver high-powered fat absorption and tissue tightening through tissue coagulation. Smartlipo Triplex will be formally launched at Plastic Surgery 2009, the American Society of Plastic Surgeons Annual Meeting, which will be held October 23-27 in Seattle.

Smartlipo Triplex adds a 1440 nm wavelength to the MPX generation of the product, and employs Cynosure’s patented MultiPlex technology to combine the benefits of three wavelengths in one laser output. MultiPlex technology enables two wavelengths to be fired sequentially, creating a blended thermal and photomechanical effect that efficiently liquefies fat and tightens skin through collagen remodeling.

“With 20 times greater absorption in fatty tissue than any other single wavelength on the market, the 1440 nm wavelength puts Smartlipo in a new class,” said Barry DiBernardo, M.D., Medical Director of New Jersey Plastic Surgery & MedNet Technologies, Inc. in Montclair, NJ. “Combining the photomechanical effects of the 1440 nm with the 1064 nm wavelength results in even greater disruption of fatty tissue for faster and deeper treatments than the 1064 wavelength alone. At the same time, the Smartlipo Triplex continues to deliver unmatched tissue tightening through tissue coagulation by blending the 1064 and 1320 nm wavelengths.”

“We continue to advance our Smartlipo family of products to address the demands of the marketplace: faster and greater absorption of fat, high-definition body sculpting capabilities and tissue tightening through tissue coagulation,” said Cynosure President and Chief Executive Officer Michael Davin. “We believe that Smartlipo Triplex enables medical professionals to deliver the most accurate combination therapy available today by providing a superior mix of energy levels and wavelengths. Whether treating a small well-defined area or removing larger amounts of fatty tissue, Smartlipo Triplex offers doctors the ability to customize the treatment to achieve maximum results. At the same time, we believe our safety features are unmatched in the industry.”

Smartlipo Triplex is equipped with SmartSense with ThermaGuide, the latest in Cynosure’s proprietary family of intelligent energy delivery systems. SmartSense with ThermaGuide is designed to work in harmony with the laser. It continually detects the temperature under the skin and controls the output of energy. This helps to ensure that the treatment area remains within a safe and optimal temperature range for fat removal and tissue tightening through tissue coagulation.

“Smartlipo Triplex is the technology of choice for my body sculpting procedures,” said John Millard, M.D., a board-certified plastic surgeon based in Denver. “It allows for quick and efficient removal of fat without excess heat – a requirement for high-definition results.”

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure’s products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about expectations for its new Smartlipo Triplex as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economic recession and its effects on the aesthetic laser industry, Cynosure’s history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure’s views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure’s views as of any date subsequent to the date of this press release.

    Contact:

    Scott Solomon
    Vice President
    Sharon Merrill Associates, Inc.
    617-542-5300
    cyno@investorrelations.com

SOURCE Cynosure, Inc.


Source: newswire



comments powered by Disqus